CTNNB1 and neoplasm: Moreover, the risk of relapse in tumours with CTNNB1 exon 3 mutation is independent of other clinicopathological prognostic factors, such as FIGO stage, tumour grade, DNA MMR-deficient protein expression, or presence of LVSI.